Peter Kiener, D. Phil

Biography

 Dr. Peter A Kiener currently is Chairman of the Board of Managers of Resolve. He is currently the Chief Scientific Officer and Head of R&D at Sucampo LLC Prior to joining Sucampo, he served as CSO of Ambrx Inc., a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates. From 2009 to 2013, Dr. Kiener was President and Co-founder of Zyngenia Inc., an early-stage biopharmaceutical company. He also held leadership roles of increasing responsibility from 2001 to 2009 at MedImmune LLC, the global biologics arm of AstraZeneca, including Executive Vice President and Global Head of Biologics Research and Development, Senior Vice President and Head of Global Research, and Vice President of Research. Dr. Kiener previously worked on biologics for Bristol-Myers Squibb from 1983 to 2001. Dr. Kiener began his career at the University of North Texas/Texas College of Osteopathic Medicine, where he was an Assistant Professor from 1982 to 1983, and the University of Massachusetts at Amherst, where he was a Research Associate from 1978 to 1982. Dr. Kiener has served on the scientific advisory boards of KAI Pharmaceuticals Inc., Genocea Biosciences Inc., NKT Therapeutics Inc. and VLST Corporation. Dr. Kiener serves as a member of the Board of Directors of Tetragenics, and Imagen Pharma LLC. He has published more than 120 papers in peer-reviewed journals and is an inventor on more than 40 patents and patent applications. Dr. Kiener earned a bachelor’s degree in chemistry from the University of Lancaster and a doctorate of philosophy in biochemistry from the University of Oxford.

Research Interest

 Dr. Peter A Kiener currently is Chairman of the Board of Managers of Resolve. He is currently the Chief Scientific Officer and Head of R&D at Sucampo LLC Prior to joining Sucampo, he served as CSO of Ambrx Inc., a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates. From 2009 to 2013, Dr. Kiener was President and Co-founder of Zyngenia Inc., an early-stage biopharmaceutical company. He also held leadership roles of increasing responsibility from 2001 to 2009 at MedImmune LLC, the global biologics arm of AstraZeneca, including Executive Vice President and Global Head of Biologics Research and Development, Senior Vice President and Head of Global Research, and Vice President of Research. Dr. Kiener previously worked on biologics for Bristol-Myers Squibb from 1983 to 2001. Dr. Kiener began his career at the University of North Texas/Texas College of Osteopathic Medicine, where he was an Assistant Professor from 1982 to 1983, and the University of Massachusetts at Amherst, where he was a Research Associate from 1978 to 1982. Dr. Kiener has served on the scientific advisory boards of KAI Pharmaceuticals Inc., Genocea Biosciences Inc., NKT Therapeutics Inc. and VLST Corporation. Dr. Kiener serves as a member of the Board of Directors of Tetragenics, and Imagen Pharma LLC. He has published more than 120 papers in peer-reviewed journals and is an inventor on more than 40 patents and patent applications. Dr. Kiener earned a bachelor’s degree in chemistry from the University of Lancaster and a doctorate of philosophy in biochemistry from the University of Oxford.